


 Cite this: *RSC Adv.*, 2024, 14, 9920

Integration of O₂-economised tumour-targeted photosensitive magnetic nanomaterials in the diagnosis and therapy of gastric cancer

 JinRong Situ,^{ab} Yingying Yang,^{ab} Lingle Zhang,^{ab} Hongzhang Yan^{ab}
 and Yingsheng Cheng^{*abc}

Hypoxia in the tumour microenvironment is a major limiting factor in photodynamic therapy. The present study employed a novel O₂-economised photosensitizer, ACSN, to effectively curtail oxygen consumption by impeding the aerobic respiration of tumour cells, thereby increasing the reactive oxygen species (ROS) production in photodynamic therapy. To enhance the efficacy of photodynamic therapy, the active targeting peptide iRGD was employed to facilitate drug accumulation in the tumour tissue. Therefore, we constructed a targeted drug platform, ACSN/Fe₃O₄@MSNs-iRGD, that integrates diagnosis and treatment. The drug exhibited excellent active targeting ability towards gastric cancer MGC-803 cells and can efficiently penetrate the mitochondria upon cellular internalisation. The photosensitizer ACSN, released from the drug, effectively suppressed mitochondrial aerobic respiration to conserve oxygen and exhibited robust ROS production upon laser excitation. The core-shell structure comprises Fe₃O₄, which offers excellent T2 dark contrast for real-time tumour monitoring through MRI imaging. By incorporating excellent photodynamic therapy and MRI imaging capabilities, this drug can serve as an effective platform for the integration of tumour diagnosis and treatment, thus addressing the limitations associated with conventional tumour therapies. It is anticipated that this approach will soon be clinically translated.

 Received 19th January 2024
 Accepted 9th March 2024

DOI: 10.1039/d4ra00497c

rsc.li/rsc-advances

1. Introduction

Malignant tumours, which are formidable adversaries to human life and health, are some of the most prominent causes of mortality. Medically referred to as cancers, these diseases exhibit exceptionally high propensity for metastasis. Based on statistical data, it is projected that the USA will witness approximately 2.00 million new cancer cases and 0.61 million cancer-related fatalities by the year 2024.¹ Among cancers, the incidence of gastric cancer ranks fifth, while it stands as the third leading cause of cancer-related mortality worldwide.² The tumour microenvironment (TME) refers to the internal milieu in which tumours originate and grow, and comprises malignant tumour cells, diverse stromal cells, and the extracellular matrix.^{3,4} Compared with normal tissues, tumour tissues and other pathological sites are typically characterised by aberrant blood vessel formation, weak acidification (pH 6.8), abnormal temperature regulation, overexpression of specific enzymes, and hypoxia.^{5,6} The specificity of TME presents challenges and opportunities for cancer treatment. On one hand, the reciprocal

interactions between cancer cells and TME contribute to increased malignancy and therapeutic resistance. The heterogeneity of the TME, such as hypoxic and acidic conditions, facilitates both tumour metastasis and drug resistance. On the other hand, leveraging the tumour-specific microenvironment as a viable target for drug delivery has immense potential for augmenting the therapeutic efficacy of drugs. Specifically, the utilisation of delivery systems that respond to the TME exhibits promising prospects for facilitating tumour-targeted delivery and controlled drug release.⁷

Early cancer diagnosis and timely treatment play pivotal roles in enhancing patient survival. Magnetic Resonance Imaging (MRI),⁸ optical imaging,⁹ photoacoustic imaging,¹⁰ ultrasonic imaging,¹¹ and computed tomography imaging,¹² are predominantly used for tumour visualisation. MRI plays a pivotal role in the diagnosis and treatment of cancer, encompassing its applications in diagnostic procedures, staging assessments, determination of optimal therapeutic approaches, and identification of tumour recurrence. In recent years, the clinical application of MRI in gastric cancer diagnosis and treatment has witnessed a remarkable surge, owing to its exceptional soft-tissue contrast and advanced imaging capabilities, encompassing multi-angle, multi-directional, and multi-parametric approaches.¹³ At present, nanoparticulate iron oxide is a popular and unique nanoparticulate agent used in

^aCollege of Fisheries and Life Science of Shanghai Ocean University, Shanghai, 201306, China. E-mail: Situ.JR@Outlook.com

^bShanghai Jiao Tong University Affiliated Sixth People's Hospital, China

^cTongji Hospital Affiliated to Tongji University, Shanghai, China



clinical practice. When applied during imaging, they reduce the intensity of the T2 signals in the tissues which absorb the contrast agent.¹⁴

Drawing upon the functional design of magnetic nanomaterials, the integration of magnetic diagnosis and treatment using multifunctional nanomaterials holds great promise in addressing a critical clinical challenge of achieving timely tumor diagnosis and treatment. Conventional treatment modalities for malignant tumours, such as radiotherapy, chemotherapy, and surgical resection, are associated with certain limitations in terms of addressing tumour recurrence and metastasis, while also causing serious toxicity and side effects.¹⁵ Reactive oxygen species (ROS)-based tumour therapies such as photodynamic therapy (PDT) and chemodynamic therapy (CDT) have promising prospects for development. PDT involves the excitation of photosensitizers under light irradiation, inducing an energy transition to generate ROS and subsequently eliminating tumour cells. This non-invasive and targeted treatment approach exhibited enhanced efficacy. PDT is concomitant with an inflammatory response that facilitates the release of various inflammatory factors and the activation of the immune system, thereby achieving autologous tumour elimination.^{16,17} Chlorine6 (Ce6), a second-generation photosensitizer, with the ability to generate high levels of singlet oxygen upon laser stimulation for tumour cell eradication, has been approved. However, aberrant angiogenesis in tumour tissues and increased cellular oxygen consumption give rise to hypoxia within the TME, thereby attenuating ROS production and compromising the therapeutic efficacy of PDT.¹⁸ Therefore, augmenting oxygen production or reducing oxygen consumption could serve as a potent strategy to enhance the efficacy of PDT. Compared with traditional photosensitizers, oxygen-economised photosensitizers can reduce cancer cells' endogenous oxygen consumption and conserve oxygen to generate increased ROS, thereby facilitating efficient PDT for hypoxic solid tumours. To this end, Zhao¹⁹ proposed a novel oxygen-economised photosensitizer, ACSN, which is synthesised by combining the cellular aerobic respiration inhibitor Atovaquone (ATO) with the photosensitizer Ce6 through π - π bond stacking and hydrophobic interactions. Due to the inhibition of mitochondrial aerobic respiration by ATO, a compound found in ACSN, effective suppression of oxygen consumption occurs at the tumour site. This counteracted the low efficiency of PDT induced by hypoxia in the TME.

The efficacy of PDT also relies on the adequate accumulation of photosensitizers at the tumour site, which, upon laser irradiation, convert oxygen molecules into ROS at specific locations and subsequently induce selective damage to the tumour while sparing normal tissues. The transport of nanomaterials to tumour cells is facilitated by enhanced permeability and retention (EPR). However, studies have demonstrated that even in translocated tumour models exhibiting high EPR effects, the passive targeting of nanomedicine remains only 0.7%.²⁰ Active-targeting drugs have been proposed to overcome the limitations of passive targeting and enhance nanomedicine transport. The disulfide bond-based loop RGD peptide-iRGD (CRGDK/RGPDC) has garnered significant attention since its initial

report by Kazuki²¹ in 2010. When chemically conjugated to a drug, iRGD facilitates the transportation of the drug into deep extravascular tumor tissue. The cell-penetrating peptide iRGD exhibits a single-ligand-multiple receptor-active targeting effect by specifically binding to multiple receptors on the surface of tumour cells. Through its interaction with the highly expressed integrin and neuropilin-1 receptors, iRGD effectively targets tumour cells and penetrates tumour tissues. Compared with traditional integrin-targeting RGD peptides, iRGD demonstrated superior tumour-targeting efficacy and enhanced penetration ability.²²

In the present study, we aimed to develop an active-targeting nanomedicine, ACSN/Fe₃O₄@MSNs-iRGD. Notably, we demonstrated that the combination of Fe₃O₄ T2 high-contrast MRI and PDT with a novel O₂-economised photosensitizing agent enabled real-time monitoring of tumour diagnosis and efficient treatment. We also tested the physicochemical properties of the drug and systematically investigated its MRI imaging and PDT therapeutic effects *in vitro* and *in vivo*. First, the drug's shell core comprised superparamagnetic Fe₃O₄ nanoparticles that exhibit a high T2-weighted relaxation rate owing to their exceptional chemical stability, non-toxicity, and biodegradability. Therefore, it represents a pioneering magnetic-nanoparticle-based contrast agent that has gained widespread use in MRI,²³ which enables real-time tumour monitoring by MRI. Second, the design of O₂-economised photosensitizer was used to deal with the limitation of hypoxia in TME, which can enhance the efficacy of PDT. Finally, iRGD was used for lactone. Above, ACSN/Fe₃O₄@MSNs-iRGD acts both as excellent real-time MRI diagnosis, and as a new strategy to overcome the limitations of low ROS production and non-targeting in PDT. The utilization of this drug significantly contributes to the seamless integration of tumor diagnosis and treatment.

2. Experimental section

2.1 Materials

Chlorin E6, Atovaquone, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC HCl), and *N*-carboxy-thiosuccinimide (sulfo-NHS) were purchased from Shanghai Yuanye Biotechnology Co., Ltd. Dimethyl sulfoxide (DMSO) was purchased from Beijing LABGIC technology Co., Ltd; mono-disperse carboxylic magnetic mesoporous silica nanomaterials (Fe₃O₄@MSNs) were purchased from Nanjing NANO EAST Biotech Co., Ltd; targeted peptide (iRGD) was purchased from Hefei Bank Peptide Biological technology Co., Ltd; 1,3-diphenylisobenzofuran (DPBF) was purchased from Shanghai Macklin Biochemical Co., Ltd; PBS buffer solution was purchased from Beijing Rangeke Technology Co., Ltd; DMEM medium, peptide bovine serum (FBS), trypsin, EDTA-free trypsin and double antibody (PS) were purchased from Thermo Fisher Scientific. 4',6-Diamidino-2-phenylindole (DAPI), 4% paraformaldehyde, and electron microscope fixative were purchased from Wuhan Servicebio Technology Co., Ltd; cck8 kit and AnnexinV-FITC/PI double staining apoptosis detection kit were purchased from Jiangsu KeyGEN BioTECH Co., Ltd; 2',7'-dichlorofluorescein diacetate (DCFH-DA) and calcein/PI cell



activity and cytotoxicity detection kits were purchased from Shanghai Beyotime Biotechnology Co., Ltd.

2.2 Preparation and characterization of ACSN/Fe₃O₄@MSNs-iRGD drugs

2.2.1 Preparation of photosensitizer, ACSN. The ACSN preparation method was adapted from a previous study.¹⁹ Initially, 4.5 mg of Ce6 and 9 mg of ATO were dissolved in DMSO to obtain solutions with concentrations of 10 mg mL⁻¹ and 7.5 mg mL⁻¹, respectively. Subsequently, a mixture containing 450 μL of Ce6 solution and 1250 μL of ATO solution was stirred for a duration of 4 h. Next, 40 mL of double steamed water (ddH₂O) was added, and the mixture was sonicated for 30 min, followed by continuous stirring overnight. Subsequently, ACSN was subjected to dialysis using a dialysis bag with a molecular weight cut-off (MWCO) of 1000 Da for one day and night, followed by centrifugation at 3000 rpm for 10 min. The resulting ACSN pellets were collected and resuspended in absolute ethanol.

2.2.2 Fe₃O₄@MSNs-iRGD and preparation. The mixture of 160 mg EDC·HCl and 20 mg sulfo-NHS was dissolved in 5 mL ddH₂O, followed by the addition of 1 mL Fe₃O₄@MSNs solution (2.5 mg mL⁻¹). The resulting mixture was stirred for 1 h using a rotary mixer. Subsequently, centrifugation at 10 000 rpm for 10 min was performed to remove the supernatant, and the carboxyl-activated Fe₃O₄@MSNs were collected by resuspension in absolute ethanol. Next, 2 mg iRGD was added and allowed to react fully overnight at 4 °C in a rotary mixer to obtain Fe₃O₄@MSNs-iRGD.

2.2.3 ACSN/Fe₃O₄@MSNs-iRGD and preparation. ACSN was thoroughly mixed with an absolute ethanol solution of Fe₃O₄@MSNs-iRGD in a rotary mixer for 24 h. Subsequently, the mixture was centrifuged at 10 000 rpm for 10 min to remove the supernatant and the ACSN/Fe₃O₄@MSNs-iRGD samples were collected.

2.2.4 Characterization of ACSN/Fe₃O₄@MSNs-iRGD. The morphology of the samples was investigated using Transmission Electron Microscopy (Tecnai G2 spirit Biotwin, Thermofisher, America). Samples for Transmission Electron Microscopy (TEM) were prepared by natural drying of 5 μL Fe₃O₄@MSNs and ACSN/Fe₃O₄@MSNs-iRGD solution after ultrasonic on a copper grids. The potentials of the samples were analysed using a laser particle-size meter (Zetasizer Nano ZS, Malvern Panalytical, England), which samples were prepared by ultrasonic under neutral conditions. Using an enzyme-labelled instrument (iMark/xMark, Bio-Rad, America) to test the characteristic absorption peaks, which samples with a 300–800 nm wavelength laser source on the spectral scanning method, and a mixture of 4 mM DPBF and 20 mg mL⁻¹ ACSN/Fe₃O₄@MSNs-iRGD was irradiated with a 633 nm laser for 5 minutes, then the generation of ROS *in vitro* was detected by detecting the absorption light at 420 nm. The freeze-dried sample powder was loaded in a Fourier Transform Infrared (Nicolet 6700, Thermofisher, America) spectrometer, scanning from 400 cm⁻¹ to 4000 cm⁻¹, which was used to investigate the distinctive chemical bonds (C=O and N-H) present in the peptide bonds.

2.3 Cell culture

MGC-803 cells, purchased from Beijing Innochem Co., Ltd, were used for both the *in vitro* and *in vivo* experiments. The cells were cultured at 37 °C in a 5% CO₂ incubator using DMEM medium supplemented with 10% foetal bovine serum and 1% double antibody.

2.3.1 Cell uptake

2.3.1.1 Laser confocal microscopy. The MGC-803 cells (1 × 10⁵) were evenly distributed in a laser confocal dish. Once the cells adhered to the wall and proliferated, the medium was aspirated, and ACSN/Fe₃O₄@MSNs-iRGD and ACSN/Fe₃O₄@MSNs drugs (2 μg mL⁻¹) were added respectively. After incubation for a specific duration (2 and 12 h), the medium was removed by aspiration, followed by washing with PBS thrice. Subsequently, 1 mL of 4% paraformaldehyde was added for fixation at room temperature in the dark for 30 min. Subsequently, the cells were washed thrice with PBS, followed by the addition of 1 mL of PBS for observation and imaging using a laser confocal microscope. The excitation wavelengths used were 405 nm and 633 nm for DAPI and ACSN, respectively.

2.3.1.2 Flow cytometry. MGC-803 cells (1 × 10⁵) were evenly distributed in six-well plates. After the cells adhered and proliferated, ACSN/Fe₃O₄@MSNs-iRGD and ACSN/Fe₃O₄@MSNs (2 μg mL⁻¹) were added respectively. Following incubation for a specific duration (2 and 12 h), the medium was aspirated, and the wells were washed thrice with PBS. Subsequently, 200 μL trypsin was added to each well and incubated at 37 °C for 2 min to facilitate digestion. The digestion was terminated by adding 1 mL of serum-free medium. Subsequently, the cells were collected in a 1.5 mL centrifuge tube and centrifuged at 1300 rpm for 3 min, followed by aspiration of the supernatant. After resuspending the cells in 500 μL PBS, flow cytometry was employed to detect the fluorescence intensity of ACSN in each group.

2.3.1.3 Observation of cells by transmission electron microscopy. MGC-803 cells (1 × 10⁵) were seeded evenly into small culture dishes. After the cells adhered and proliferated, ACSN/Fe₃O₄@MSNs and ACSN/Fe₃O₄@MSNs-iRGD (2 μg mL⁻¹), prepared using serum-free medium, were added. The cells were then incubated for 6 h. Subsequently, the medium was aspirated, and the cells were washed thrice with PBS before adding 200 μL of trypsin for digestion at 37 °C for 2 min. Finally, digestion was terminated by adding 1 mL of serum-free medium. The cells were then collected in a 1.5 mL centrifuge tube and centrifuged at 1300 rpm for 3 min to remove the supernatant. Subsequently, the cells were resuspended in 1 mL of electron microscopy fixative and sent to Wuhan Savier Biotechnology Co., Ltd for cell section preparation, followed by observation and photography using a transmission electron microscope.

2.3.2 Cytotoxicity. All MGC-803 cells, amounting to 5 × 10³, were evenly distributed in a 96-well plate with PBS surrounding the periphery. Four compound wells were used for each group. Upon cell attachment to the wall and growth, the medium was removed and 100 μL of ACSN/Fe₃O₄@MSNs-iRGD, prepared with varying concentrations (0.5, 2, 4, 6, 8, and 10 μg mL⁻¹) of



serum-free medium, was added to each well. The same volume of PBS was added to the control group, followed by a 24 h incubation. To assess the dark- and photo-toxicities of the drugs, dark treatment groups (incubated for 24 and 48 h) and laser treatment groups (incubated for 24 h) were established. Cells in the dark treatment group were incubated for 24 and 48 h in a 5% CO₂ incubator at 37 °C without laser irradiation. The laser-treated group was exposed to 633 nm (0.5 W cm⁻²) laser control for 5 min, followed by a 24 h incubation. The medium was aspirated, and the wells were washed thrice with PBS. Subsequently, 100 μL of a 10% CCK-8 solution was added to each well, and the 96-well plates were incubated for an additional 1 h. Finally, the optical density (OD) of the samples was measured at 450 nm using a microplate reader.

2.3.3 Detection of intracellular ROS

2.3.3.1 Laser confocal microscopy. The 1 × 10⁵ MGC-803 cells were evenly dispersed in a laser confocal dish. Upon cell attachment and growth, the medium was carefully removed and 2 μg mL⁻¹ of drugs Ce6, ACSN, and ACSN/Fe₃O₄@MSNs-iRGD were sequentially added to each dish. In the control group, an equal volume of PBS was administered, and the cells were incubated for 24 h. The dish was subsequently aspirated and washed thrice with PBS before adding 1 mL serum-free medium. To investigate the effect of laser irradiation on ROS generation by photosensitizers in the drug, dark and laser treatment groups were established. The dark treatment group was excluded from laser irradiation, while the laser treatment group was exposed to a 633 nm (0.5 W cm⁻²) laser for 5 min. Subsequently, the dish was aspirated, and 1 mL of 10 mM DCFH-DA was added to the cells for 30 min. The cells were then washed thrice with PBS to remove excess extracellular DCFH-DA probes. Finally, 1 mL of serum-free medium was added, and the dish was placed in a laser confocal microscope for observation and imaging. The green fluorescence of 2',7'-dichlorofluorescein (DCF), generated by the combination of ROS and DCFH-DA probe in the cells, was employed as an indicator, with the excitation wavelength set at 504 nm.

2.3.3.2 Flow cytometry. The 1 × 10⁵ MGC-803 cells were evenly dispersed in a six-well plate. After they adhered to the wall and proliferated, the medium was removed and 2 μg mL⁻¹ of drugs (Ce6, ACSN, and ACSN/Fe₃O₄@MSNs-iRGD prepared with serum-free medium) were added to each well. The cells in the control group were supplemented with equal amounts of PBS and incubated for 24 h. The medium was subsequently aspirated and washed thrice with PBS, followed by the addition of 1 mL of serum-free medium to each well. To investigate the effect of laser irradiation on the production of ROS by photosensitizers in the drug, dark and laser treatment groups were established, as previously mentioned. Subsequently, the medium was aspirated, 1 mL of 10 mM DCFH-DA was added, and the cells were incubated for 30 min. Finally, the cells were washed thrice with PBS to completely remove the excess extracellular DCFH-DA probe. An additional 200 μL of EDTA-free trypsin was added to each well and incubated at 37 °C for 2 min, followed by the addition of 1 mL of serum-free medium to terminate the digestion. The cells were collected in a 1.5 mL centrifuge tube, centrifuged at 1300 rpm for 3 min, and the supernatant was aspirated. The cells were resuspended in 500

μL PBS, and the green fluorescence intensity of DCF in each group was detected by flow cytometry, with the fluorescence channel being fluorescein isothiocyanate (FITC).

2.3.4 Cell apoptosis. The 1 × 10⁵ MGC-803 cells were evenly dispersed in a six-well plate and allowed to adhere to the wall and proliferate. Subsequently, the medium was aspirated and 2 μg mL⁻¹ of drugs Ce6, ACSN, and ACSN/Fe₃O₄@MSNs-iRGD, prepared using serum-free medium, were added to each well separately. The control group received the same volume of PBS and both groups were incubated for 24 h. Thereafter, the medium was aspirated, and 1 mL of serum-free medium was added to each well after washing with PBS thrice. Dark and laser treatment groups were established to investigate the *in vitro* dark- and photo-toxicities of the drugs. The dark treatment group was not exposed to laser radiation, whereas the laser treatment group was irradiated, as previously stated, followed by a 6 h incubation. The medium was aspirated, and 200 μL of EDTA-free trypsin was added to each well, which was incubated at 37 °C for 3 min, after which 1 mL of serum-free medium was added to terminate the digestion. The cells were collected into a 1.5 mL centrifuge tube, centrifuged at 1300 rpm for 3 min to remove the supernatant, and then gently resuspended in 500 μL of binding buffer. After mixing with 5 μL of Annexin V-FITC, 5 μL of propidium iodide was added. The reaction was performed at room temperature in the dark for 5 min. The apoptosis rate of the cells in each group was determined by flow cytometry using the FITC and PI fluorescence channels.

2.3.5 Staining of live and dead cells. The 1 × 10⁵ MGC-803 cells were evenly dispersed in a six-well plate. After the cells attached to the wall and proliferated, the medium was aspirated and 2 μg mL⁻¹ of drugs Ce6, ACSN, and ACSN/Fe₃O₄@MSNs-iRGD prepared in serum-free medium were added to each well. The cells in the control group received equal amounts of PBS and were incubated for 24 h. Subsequently, the medium was aspirated, and 1 mL of serum-free medium was added to each well after washing with PBS thrice. Dark and laser treatment groups were established to investigate the *in vitro* dark- and photo-toxicities of the drugs. The dark treatment group was not exposed to laser radiation, whereas the laser treatment group was irradiated as previously stated for 5 min and then incubated for 4 h. To circumvent the error caused by floating dead cells being dislodged, 1 mL of detection buffer, 1 μL of PI (1000×), and 1 μL of calcein AM (1000×) were added to each well directly, followed by a 30 min incubation in the incubator. The staining effect was observed by fluorescence microscopy.

2.4 In vivo experiments

2.4.1 Construction of animal models. Five-week-old BALB/c-nude female mice purchased from Jiangsu Jichi Pharmaceutical Kang Biotechnology Co., Ltd were allowed 1 week adaptation. Subsequently, a subcutaneous MGC tumour was grafted into the right hind limb of the mice. Upon reaching a volume of approximately 100 mm³, the tumours were used for subsequent experiments.

2.4.2 In vivo fluorescence imaging. To investigate the targeting efficacy of the drug and observe the degree of drug



aggregation at the tumour site as well as its metabolism in the body, to determine the optimal time point for laser irradiation after drug administration, two mice were selected for fluorescence imaging (IVIS spectrum, PerkinElmer, America) of ACSN/Fe₃O₄@MSNs and ACSN/Fe₃O₄@MSNs-iRGD, respectively. A chemiluminescence fluorescence imaging analysis system was employed to collect real-time fluorescence imaging results at various time points before and after tail vein injection with 1 mg kg⁻¹ doses of ACSN/Fe₃O₄@MSNs and ACSN/Fe₃O₄@MSNs-iRGD.

2.4.3 Magnetic resonance imaging (MRI). Medical imaging technologies such as magnetic resonance imaging (CG NOVILA 7.0T, ChenGuang, China) provide a non-invasive method for visualising body tissues, organs, or lesions. In clinical practice, they are used extensively to diagnose the presence, size, and location of lesions. Contrast agents are frequently employed in diagnostic imaging to enhance the contrast between lesions and normal tissues. To assess the *in vivo* MRI effects of ACSN/Fe₃O₄@MSNs-iRGD, imaging was conducted using a 7.0 T MRI scanner 6 h after the administration of 1 mg kg⁻¹ ACSN/Fe₃O₄@MSNs-iRGD *via* the tail vein. The reciprocal relaxation time (1/T) with respect to the iron concentration and transverse relaxation rate (*r*) were obtained through linear fitting.

2.4.4 PDT. To investigate the antitumor efficacy of the PDT, mice bearing MGC-803 cell-derived tumours were randomly assigned to five groups: blank control (injected with an equal volume of normal saline), ACSN/Fe₃O₄@MSNs-iRGD, ACSN/Fe₃O₄@MSNs + laser, Ce6/Fe₃O₄@MSNs-iRGD + laser, and ACSN/Fe₃O₄@MSNs-iRGD + laser. Each group comprised three replicates. Mice in the blank control and ACSN/Fe₃O₄@MSNs-iRGD groups were not exposed to laser therapy, while the tumour regions in the other groups were irradiated with a 633 nm (0.5 W cm⁻²) laser for 5 min, 6 h after drug administration. All the other conditions remained unchanged. Tumour volume was measured using a Vernier calliper at designated time points throughout a consecutive 14 days treatment cycle. Following the conclusion of the treatment, the tumours were collected, photographed, and sent to Wuhan Savier Biotechnology Co., Ltd for H&E staining, TUNEL staining, and Ki67 immunohistochemical staining.

2.4.5 Safety evaluation. Body weights of the mice were periodically assessed using an electronic balance throughout 14 days treatment cycles. On day 14 of the treatment, orbital blood samples were collected from the mice, and these samples were subsequently placed in anticoagulant tubes and forwarded to Wuhan Savier Biotechnology Co., Ltd for routine blood analysis. Tumour tissues, including the heart, liver, spleen, lungs, and kidneys, were meticulously collected, and fixed using a tissue fixative solution for 24 h. The heart, liver, spleen, lungs, and kidneys were stained with H&E and observed under a fluorescence microscope.

3. Results and discussion

3.1 Preparation and characterization of ACSN/Fe₃O₄@MSNs-iRGD materials

The distinctive advantage of mesoporous silica is that they have well-defined surface properties that allow easy functionalization

of the silanol-containing surface. Moreover, the external surface can be conjugated with targeting ligands for efficient cell-specific drug delivery.^{24,25} This truly facilitates targeted peptide iRGD modification. The drug's morphology and size were observed using TEM (Fig. 1a–c). Sample ACSN/Fe₃O₄@MSNs-iRGD was a homogeneous mesoporous spherical structure with an Fe₃O₄ core coated with mesoporous silica, on which the photosensitizer ACSN was loaded. Thus, the permeability of the mesoporous layer was lower than that of the Fe₃O₄@MSNs. The size of Fe₃O₄@MSNs was approximately 117 nm, whereas that of ACSN/Fe₃O₄@MSNs-iRGD was 151 nm. Photosensitizer ACSN was self-assembled by Ce6 and ATO through π - π interaction. At pH 7.0, the zeta potentials of Ce6, ATO, and ACSN (Fig. 1d) were -27.3 mV, -15 mV, and -23.3 mV, respectively, with ACSN's negative potential between that of Ce6 and ATO. Zeta potentials (Fig. 1e) for Fe₃O₄@MSNs, Fe₃O₄@MSNs-iRGD, and ACSN/Fe₃O₄@MSNs-iRGD were 16.8 mV, -10.8 mV, and -21.7 mV, respectively. iRGD was conjugated to the carboxyl group on the surface of the Fe₃O₄@MSNs, and the photosensitizer ACSN was doped into the mesoporous silicon layer. Negatively charged iRGD and ACSN offset the positive charge of mesoporous silica, allowing easier absorption into the cells through the cell membrane, thereby improving the effectiveness of drug delivery. Meanwhile, the negative charge on the surface can attract ions with opposite charges and facilitate their dispersion. UV-visible spectrum analysis (Fig. 1f) further demonstrated a red-shifted absorption peak (approximately 30 nm) for ACSN/Fe₃O₄@MSNs-iRGD in the 600–700 nm range compared to that of Ce6, owing to the interaction between the Photosensitizer ACSN (Ce6) and the magnetic material, indicating that ACSN was doped into mesoporous silica Fe₃O₄. Fourier transform infrared spectroscopy (Fig. 1g) revealed characteristic absorption peaks of peptide bonds (C=O, N-H) at 1645 cm⁻¹ and 3375 cm⁻¹, demonstrating that the target peptide, iRGD, dehydrates and condenses with the activated carboxyl group of the mesoporous silicon layer. Meanwhile, the absorption peaks at 1072 cm⁻¹ (C-C) increased due to the addition of peptide, successfully demonstrating the incorporation of the drug into the target peptide.²⁶ Finally, due to its rapid and accurate detection of oxygen concentration, DPBF exhibits an absorption peak at 420 nm, a decrease in this absorption peak was used to assess the photodynamic generation of ROS in ACSN/Fe₃O₄@MSNs-iRGD (Fig. 1h). After 5 min of 633 nm (0.5 W cm⁻²) laser irradiation, the absorbance at 420 nm decreased from 3.869 to 2.096 in 4 min, reaching 54.17%. These findings suggest that ACSN/Fe₃O₄@MSNs-iRGD can generate a substantial amount of ROS following laser excitation, thus exhibiting a promising PDT effect.

3.2 *In vitro* cell experiments

3.2.1 Cellular uptake

3.2.1.1 Laser confocal microscopy. ACSN (Ce6) emits excitable red light at 633 nm, whereas DAPI can bind to double-stranded DNA to produce excitable blue light at 488 nm. Consequently, the red fluorescence intensity could be quantified to reflect the amount of intracellular drug uptake. As






Fig. 1 TEM images of Fe₃O₄@MSNs (a) and ACSN/Fe₃O₄@MSNs-iRGD (b); semi-quantitative analysis of Fe₃O₄@MSNs and ACSN/Fe₃O₄@MSNs-iRGD (c); the zeta potentials of Ce6, ATO, ACSN (d) and Fe₃O₄@MSNs, Fe₃O₄@MSNs-iRGD, ACSN/Fe₃O₄@MSNs-iRGD (e); UV-vis spectrum of Ce6, iRGD, Fe₃O₄@MSNs, ACSN/Fe₃O₄@MSNs-iRGD (f); the Fourier transform infrared of Fe₃O₄@MSNs and ACSN/Fe₃O₄@MSNs-iRGD (g). OD of ROS produced by ACSN/Fe₃O₄@MSNs-iRGD at 420 nm *in vitro* before and after laser irradiation (h).

observed using laser confocal microscopy (Fig. 2a), the blank control group supplemented with equal amounts of PBS did not exhibit red fluorescence. In contrast, the red fluorescence intensity increased with the incubation time in cells incubated with ACSN/Fe₃O₄@MSNs without targeted drugs and ACSN/Fe₃O₄@MSNs-iRGD with targeted drugs for 2 and 12 h, respectively. Cells were primarily concentrated in the nucleus. Semi-quantitative analysis of the red fluorescence (Fig. 2b) revealed that the uptake of the targeted drug ACSN/Fe₃O₄@MSNs-iRGD was significantly higher than that of the non-targeted drug ACSN/Fe₃O₄@MSNs at the same drug concentration and incubation time, indicating that the drug possesses potent targeting capabilities.

3.2.1.2 Flow cytometry. The intracellular drug uptake was quantified using flow cytometry (Fig. 2c). The red fluorescence intensity of ACSN increased proportionally with the duration of drug incubation. The fluorescence intensity of ACSN/Fe₃O₄@MSNs-iRGD, administered with the same targeted drug concentration simultaneously, was notably superior to that of ACSN/Fe₃O₄@MSNs sans targeted drug. Furthermore, in the post-mean fluorescence intensity analysis (Fig. 2d), the drug uptake of ACSN/Fe₃O₄@MSNs-iRGD incubated for 2 h exceeded that of ACSN/Fe₃O₄@MSNs incubated for 12 h without targeted drug uptake. This validated the function of the targeted peptide, iRGD, demonstrating its ability to accelerate the uptake rate and enhance drug uptake.

The results of the flow cytometry-based quantitative detection corresponded with those of laser confocal microscopy,

indicating that ACSN/Fe₃O₄@MSNs-iRGD has potent targeting ability towards MGC-803 cells. Consequently, damage to healthy tissues can be minimised upon drug entry into the body, ensuring sufficient accumulation of the drug at the tumour site, thereby guaranteeing the therapeutic efficacy of PDT and achieving accurate targeted therapy.

3.2.1.3 Biotype transmission electron microscopy. To elucidate the drug efficacy of PDT, it is crucial to ascertain the drug distribution in MGC-803 cells. Employing transmission electron microscopy to visualise the internalised drug distribution within cells demonstrated that most non-targeted drugs ACSN/Fe₃O₄@MSNs (Fig. 2e) were not taken up by cells, with only a few exceptions; conversely, a majority of the targeted drug ACSN/Fe₃O₄@MSNs-iRGD could enter cells and further translocate into mitochondria (Fig. 2f). Consequently, ACSN (ATO) released by ACSN/Fe₃O₄@MSNs-iRGD interacted with the mitochondrial electron transport chain and inhibited cellular aerobic respiration, thereby reducing oxygen consumption. Hence, the increased oxygen supply to tumour tissues can be utilised to generate ROS and enhance the lethality of PDT.

3.2.2 Cytotoxicity. The cck-8 reagent was used to assess the *in vitro* drug toxicity of ACSN/Fe₃O₄@MSNs-iRGD on MGC-803 cells (Fig. 3a). To confirm the absence of cell damage induced by ACSN/Fe₃O₄@MSNs-iRGD in the absence of laser irradiation, we established a dark-treatment group. Incubation of cells with different concentrations of the drug for 24 and 48 h did not result in a significant change in the cell survival rate, suggesting that the drug was safe without laser treatment. Furthermore, to




Fig. 2 Results of cellular drug uptake. Laser confocal images (a) and semi-quantitative analysis (b) of MGC-803 cells incubated with non-targeted drug ACSN/Fe₃O₄@MSNs and targeted drug ACSN/Fe₃O₄@MSNs-iRGD for 2 and 12 h, respectively. Flow cytometry was used to measure the fluorescence intensity of cell uptake (c) and mean fluorescence intensity analysis (d). Biological image observation by transmission electron microscopy of cellular drug uptake, and the uptake of non-targeted drug ACSN/Fe₃O₄@MSNs (e) and targeted drug ACSN/Fe₃O₄@MSNs-iRGD (f) in MGC-803 cells. Distribution of the drug ACSN/Fe₃O₄@MSNs-iRGD in mitochondria after internalization (f 2, and 3), with red arrows pointing to the drug.

validate the *in vitro* PDT potential of the drug, a laser treatment group was established. Treatment of the cells with 633 nm (0.5 W cm^{-2}) laser led to a gradual decrease in cell survival rate with increasing drug concentration. These findings indicated that the PDT induced by the drug can eradicate tumour cells. Although the drug demonstrated significant

cytotoxicity following laser treatment, it remained safe and nontoxic to cells in the absence of laser irradiation. Therefore, the drug can be utilised as a relatively safe tumour treatment agent, specifically targeting the tumour growth site with laser radiation to achieve effective treatment of tumours in local regions.






Fig. 3 Graphs of the cytotoxicity assay and reactive oxygen species detection. Figure of cytotoxicity assay detection results (a), different concentrations of ACSN/Fe₃O₄-iRGD and MGC-803 cells incubated in the dark for 24 h and 48 h, and irradiated with 633 nm (0.5 W cm⁻²) laser for 24 h, respectively. Intracellular reactive oxygen species detection results, confocal laser images (b), and semi-quantitative analysis (c) of reactive oxygen species produced in MGC-803 cells incubated with the same concentrations of Ce6, ACSN, and ACSN/Fe₃O₄-iRGD in the dark and under laser treatment; fluorescence intensity of intracellular reactive oxygen species was measured by flow cytometry (d).

3.2.3 Detection of intracellular ROS

3.2.3.1 Laser confocal microscope observation. The non-fluorescent probe DCFH-DA can enter cells through free diffusion, where it is hydrolysed by intracellular lipase to DCFH. This derivative is then oxidised by intracellular ROS to DCF, which exhibits green fluorescence and is loaded into cells. Consequently, the intensity of the intracellular green fluorescence can be used to reflect ROS levels. Laser confocal microscopy and semi-quantitative analysis of green fluorescence (Fig. 3b and c) showed no significant ROS generation in the blank control group and the three drug-treated groups (Ce6, ACSN, and ACSN/Fe₃O₄@MSNs-iRGD) without laser irradiation. However, after 633 nm (0.5 W cm⁻²) laser irradiation for 5 min, the green fluorescence intensity of ACSN at the same concentration was notably higher than that of Ce6. This was attributed to ACSN, an oxygen-economised photosensitizer that inhibits oxygen consumption in cells at similar oxygen levels, allowing for more oxygen accumulation in cells, thereby elevating ROS levels. These findings demonstrate a significantly more potent PDT effect for ACSN than for Ce6. The green fluorescence signal in the ACSN/Fe₃O₄@MSNs-iRGD group was the most robust following laser treatment, potentially because of the active targeting capability of the drug complex, which enabled greater accumulation of drugs in tumour cells under the same drug concentration incubation, thereby significantly enhancing PDT efficacy.

3.2.3.2 Flow cytometry. ROS production in the cells was quantitatively detected by flow cytometry (Fig. 3d). Under non-laser irradiation, a small amount of ROS was observed in the cells, with the lowest production observed in the ACSN/Fe₃O₄@MSNs-iRGD group, indicating the enhanced biological drug safety following modification. Pure laser irradiation did not induce ROS production. After 633 nm (0.5 W cm⁻²) laser irradiation for 5 min, the ROS production in the three drug groups (Ce6, ACSN, and ACSN/Fe₃O₄@MSNs-iRGD) significantly increased (ACSN/Fe₃O₄@MSNs-iRGD group > ACSN group > Ce6 group). The PDT effect of ACSN as a photosensitizer was superior to that of Ce6. Due to the targeting ability of Fe₃O₄@MSNs-iRGD-ACSN, cell uptake under the same drug concentration was greater, resulting in the highest amount of ROS produced.

This result is consistent with the findings of laser confocal microscopy. Under the same conditions, the ability of the drug to produce ROS after laser excitation was: ACSN/Fe₃O₄@MSNs-iRGD was significantly greater than that of ACSN and Ce6, thus demonstrating the excellent PDT effect of ACSN/Fe₃O₄@MSNs-iRGD in tumour treatment.

3.2.4 Cell apoptosis. The effect of PDT on apoptosis was assessed using an apoptosis assay kit and flow cytometry (Fig. 4a). No significant cell apoptosis was observed in the blank control group or the three drug treatment groups (Ce6, ACSN, and ACSN/Fe₃O₄@MSNs-iRGD), with a normal cell survival rate






Fig. 4 Graphs showing the results of apoptosis and staining of live and dead cells. Apoptosis results of MGC-803 cells treated with the same concentration of Ce6, ACSN, and ACSN/Fe₃O₄-iRGD in the dark and 633 nm (0.5 W cm⁻²) laser irradiation (a) and live-dead cell detection by calcein-Ca and PI staining (b).

exceeding 88%. The late apoptosis rate in the laser group increased marginally; however, the normal cell survival rate remained high (81.7%), indicating no significant cytotoxic effect. After administering different drugs (Ce6, ACSN, and ACSN/Fe₃O₄@MSNs-iRGD) in conjunction with laser treatment at 633 nm (0.5 W cm⁻²), the early and late apoptosis rates of the ACSN group increased from 25.7% to 44.4% and from 5.74% to 12.2%, respectively, whereas the normal cell survival rate declined from 62.5% to 42.5%. The oxygen-sparing photosensitizer ACSN generated higher levels of ROS by conserving more toxic oxygen, resulting in a more pronounced PDT effect than Ce6, which significantly promoted cell apoptosis. Among the three drug groups, the ACSN/Fe₃O₄@MSNs-iRGD group exhibited the highest apoptosis rate, with early and late apoptosis rates of 40.2% and 27.0%, respectively, and a cell survival rate of 30.7%. As ACSN/Fe₃O₄@MSNs-iRGD possesses targeting properties and accumulates in cells, the cytotoxic effect of laser treatment on cells was intensified, leading to a more significant PDT effect. Following 633 nm (0.5 W cm⁻²) laser irradiation, the drug ACSN/Fe₃O₄@MSNs-iRGD demonstrated a significant apoptotic effect on cells. Owing to the targeting capabilities of ACSN as an oxygen-sparing photosensitizer and iRGD, the drug ACSN/Fe₃O₄@MSNs-iRGD induced the strongest cytotoxic effect on tumour cells when used in PDT.

3.2.5 Staining of live-dead cells. The effect of PDT on cell activity was investigated using a live/dead cell staining kit in conjunction with fluorescence microscopy (Fig. 4b). Live cells were stained with calcein AM, which generates green fluorescence, whereas dead cells were stained with PI, which produces

red fluorescence. The green fluorescence intensity in the pure drug and pure laser irradiation groups was noticeably higher than the red fluorescence, suggesting that this treatment led to a high cell survival rate and did not result in significant cell death. By incorporating different drugs (Ce6, ACSN, and ACSN/Fe₃O₄@MSNs-iRGD) and a 633 nm (0.5 W cm⁻²) laser therapy, the red fluorescence of the ACSN group was significantly augmented compared to that of the Ce6 group, indicating that the ACSN group demonstrated a more potent cell-killing effect following PDT than the Ce6 group. Furthermore, the ACSN/Fe₃O₄@MSNs-iRGD group exhibited the highest red fluorescence and cell death rate, suggesting that at the same drug concentration, ACSN/Fe₃O₄@MSNs-iRGD might possess a more efficient PDT effect because of its easier cell entry compared with pure Ce6 and ACSN, despite its targeting drug properties. The drug exhibited a lethal effect on the cells following laser irradiation at 633 nm (0.5 W cm⁻²) laser irradiation. Owing to the combined targeting effects of ACSN as an oxygen-economised photosensitizer and iRGD, ACSN/Fe₃O₄@MSNs-iRGD demonstrated the most potent cell-killing effect on tumour cells in PDT.

3.3 *In vivo* experiments

3.3.1 Dual-modality imaging

3.3.1.1 Fluorescence imaging. The use of distinct colours enables the display of varying fluorescence intensities, with the fluorescence intensity decreasing in the following order: red, yellow, green, and blue. As illustrated in Fig. 5a, following tail vein injection of the nontargeted drug ACSN/Fe₃O₄@MSNs, the



fluorescence signal at the tumour site was weak, with the signal predominantly localised in the kidney and liver. In addition, the overall *in vivo* fluorescence of the drug was faint, suggesting a rapid metabolic rate with no significant aggregation at the tumour site. However, robust fluorescence signals were detected in the tumour area 6 h after the injection of the targeted drug ACSN/Fe₃O₄@MSNs-iRGD through the tail vein. A high fluorescence signal was maintained in the tumour at 8 and 12 h post injection, with significant metabolism observed in the kidney and liver at 24 h post injection. These findings imply that the iRGD-conjugated drug could effectively accumulate at the tumour site, ensuring the efficacy of PDT. By comparing the fluorescence signal intensities of ACSN/Fe₃O₄@MSNs and ACSN/Fe₃O₄@MSNs-iRGD in the tumour, kidney, and liver at the same concentration and time, it was evident that ACSN/Fe₃O₄@MSNs-iRGD exhibited greater aggregation in the tumour. The aggregation time of the targeted drug in tumours is longer, which could significantly delay metabolism. In contrast, the non-targeted drug ACSN/Fe₃O₄@MSNs accumulated less in tumours, was metabolised rapidly, and was primarily

metabolised by the kidneys *in vivo*. The targeted drug ACSN/Fe₃O₄@MSNs-iRGD specifically targeted tumour cells, thereby reducing the impact on other normal tissues and facilitating a more efficient PDT effect.

3.3.1.2 Magnetic resonance imaging. We examined the T2 relaxation rate (Fig. 5b) and T2-weighted MRI images (Fig. 5c) of ACSN/Fe₃O₄@MSNs-iRGD at varying drug concentrations. As the drug concentration increased, the T2 relaxation rate increased correspondingly, leading to progressively darker T2-weighted MRI images. Subsequently, following the injection of ACSN/Fe₃O₄@MSNs-iRGD into the tail vein of the tumour-bearing mice, T2-weighted MRI signals were analysed (Fig. 5d). With the accumulation of the targeted drug ACSN/Fe₃O₄@MSNs-iRGD in the tumour, significant darkening of the tumour area was observed after drug injection. Consequently, ACSN/Fe₃O₄@MSNs-iRGD can serve as an MRI contrast agent, facilitating the integration of drug diagnosis and treatment.

3.3.2 *In vivo* treatment. The efficacy of PDT for tumour treatment was further assessed by establishing a subcutaneous tumour model in the right hind limb of mice. Fig. 6a and




Fig. 5 Results of dual-modality imaging in mice. (a) *In vivo* fluorescence imaging of tumour-bearing mice before and after tail vein injection of drugs (ACSN/Fe₃O₄@MSNs and ACSN/Fe₃O₄@MSNs-iRGD); white circles represent the kidney and tumour sites, respectively. Relaxation rates of ACSN/Fe₃O₄@MSNs-iRGD at different concentrations (b) and T2-weighted MRI images (c); *in vivo* T2-weighted MRI images (d) of tumour-bearing mice before and after injection of ACSN/Fe₃O₄@MSNs-iRGD *via* the tail vein; white circles represent the tumour sites.






Fig. 6 Tumours at the end of 14 days of treatment with PBS, ACSN/Fe₃O₄@MSNs-iRGD, ACSN/Fe₃O₄@MSNs + laser, Ce6/Fe₃O₄@MSNs-iRGD + laser, and ACSN/Fe₃O₄@MSNs-iRGD + laser (a); changes in tumour volume (b) and body weight (c) of tumour-bearing mice on day 0, 2, 4, 7, 10, 12, and 14 of treatment; immunohistochemical sections with H&E, TUNEL, and Ki67 staining of tumour tissue at the end of treatment (d); H&E staining of major organs (heart, liver, spleen, lung, and kidney) (e) and routine blood analysis (f).



b displays the blank control, ACSN/Fe₃O₄@MSNs-iRGD, ACSN/Fe₃O₄@MSNs + laser, Ce6/Fe₃O₄@MSNs-iRGD + laser, and ACSN/Fe₃O₄@MSNs-iRGD + laser groups. The tumour volumes of the five groups of mice at 0, 2-, 4-, 7-, 10-, 12-, and 14-days post treatment are shown. The findings indicated that the tumour volumes of the blank control group and ACSN/Fe₃O₄@MSNs-iRGD group without laser treatment significantly increased within 14 days. However, following 633 nm (0.5 W cm⁻²) laser irradiation, the tumour volumes of the ACSN/Fe₃O₄@MSNs + laser, Ce6/Fe₃O₄@MSNs-iRGD + laser, and ACSN/Fe₃O₄@MSNs-iRGD + laser treated mice were significantly inhibited within 14 days. At the end of the treatment, the tumour volume of the ACSN/Fe₃O₄@MSNs-iRGD + laser group was significantly lower than those of the other four groups, suggesting that the PDT of ACSN/Fe₃O₄@MSNs-iRGD had a more pronounced effect on the anti-tumour treatment of mice. The pathological changes in the tumour tissue were analysed by examining the H&E, TUNEL, and Ki67 stained immunohistochemical sections (Fig. 6d) at the end of treatment. The morphological structure, apoptosis, and cell proliferation of the tumour tissue in the blank control group and ACSN/Fe₃O₄@MSNs-iRGD group without laser treatment were relatively normal. However, some damage was observed in all three groups following laser treatment. H&E staining revealed that the tumour tissue vacuolisation in the ACSN/Fe₃O₄@MSNs-iRGD + laser treatment group was the most severe. TUNEL staining demonstrated the presence of many cells in apoptosis. Ki67 staining revealed a significantly reduced cell proliferation ability in the tumour tissue of the ACSN/Fe₃O₄@MSNs-iRGD + laser treatment group, indicating that PDT exerted the most potent cytotoxic effect on the tumour tissue. This treatment effectively induced apoptosis and suppressed tumour cell proliferation, demonstrating its efficacy as an anti-tumour therapy.

Compared with that in the ACSN/Fe₃O₄@MSNs + laser group, the drug in the ACSN/Fe₃O₄@MSNs-iRGD + laser group demonstrated superior tumour targeting guided by the targeted peptide iRGD. Moreover, a greater amount of the drug can accumulate at the tumour site within 6 h of injecting the same amount of drug. Consequently, the ACSN/Fe₃O₄@MSNs-iRGD + laser group exhibited a more effective PDT effect and prevented excessive drug damage in other tissues and organs. In comparison with the Ce₆/Fe₃O₄@MSNs-iRGD + laser group, ACSN/Fe₃O₄@MSNs-iRGD + laser group utilised ACSN as a photosensitizer, which is better suited to the hypoxic characteristics of the TME. By inhibiting cellular aerobic respiration, this approach conserves oxygen in the tumour environment and generates more ROS during PDT, resulting in a stronger tumour-killing effect.

3.3.3 Biosafety evaluation. To assess the *in vivo* biosafety of the drug, we used weight fluctuations of tumour-bearing mice throughout a 14 days treatment cycle, routine blood analyses of the mice at the conclusion of the cycle, and morphological/structural alterations in the main organs as indicators. The body weights of the tumour-bearing mice in each group remained relatively stable throughout the treatment period (Fig. 6c). The routine blood parameters of mice in each group were within the expected range (Fig. 6f). The hearts, livers, spleens, lungs, and kidneys of the mice in each group stained

with H&E exhibited normal structures without any obvious abnormalities (Fig. 6e). In conclusion, this drug demonstrated good biological safety in mice and did not interfere with their normal lives. This is attributed to the low dark toxicity and effective targeting of the drug, as well as the ability of laser irradiation to treat the precise site, thereby reducing damage to healthy tissues. Compared with the non-targeted traditional treatment methods such as chemotherapy and radiotherapy, PDT causes less systemic damage and maintains the normal function of the body.

4. Conclusion

In summary, this study investigated an active targeted therapeutic drug based on a transmembrane peptide that can be used for MRI imaging and PDT treatment and its inhibitory effect on gastric cancer MGC-803 cells. Compared with the commonly used photosensitizer Ce6, the novel oxygen-economised tumour photosensitizer ACSN combined the superior characteristics of Ce6 and ATO. Ce6 exhibits a high singlet oxygen production rate and low dark toxicity, rendering it suitable for PDT development. The cell respiration inhibitor, ATO, can also damage the respiratory metabolism of tumour cells and induce oxygen retention. This can alleviate the limitations of TME hypoxia during PDT, to a certain extent, thereby enhancing the PDT effect of the photosensitizer Ce6. MRI employs high light-dark contrast images to achieve non-invasive, real-time monitoring using Fe₃O₄ as the shell core, effectively reducing the T2-weighted relaxation time in MRI and obtaining enhanced dark images, facilitating real-time monitoring of tumour changes through MRI during treatment. Both *in vitro* cellular uptake and *in vivo* fluorescence imaging demonstrated that the iRGD exhibited a potent targeting effect, capable of increasing drug uptake in tumour cells and prolonging the retention time of drugs in tumours *in vivo*, thereby promoting the full potential of PDT. This drug platform demonstrated promising PDT efficacy with significant tumour volume suppression. In PDT, tissue penetration of the laser plays a crucial role in determining the therapeutic efficacy against tumours. Although the 633 nm red laser exhibits excellent tissue penetration ability and holds significant promise for broadening the application prospects of tumour PDT across various anatomical sites, for large or deeply seated tumours, the effectiveness of PDT employing 633 nm laser may be limited. We propose further research, developing oxygen-saving photosensitizers with extended absorption wavelengths. This research is vital for broadening the scope of treating large solid- and deep-seated tumours.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This work was financially supported by the National Natural Science Foundation of China (81971714).



Notes and references

- 1 R. L. Siegel, A. N. Giaquinto and A. Jemal, *Ca-Cancer J. Clin.*, 2024, **74**, 12–49.
- 2 E. C. Smyth, M. Nilsson, H. I. Grabsch, N. C. van Grieken and F. Lordick, *Lancet*, 2020, **396**, 635–648.
- 3 T. Wu and Y. Dai, *Cancer Lett.*, 2017, **387**, 61–68.
- 4 S. Peng, F. Xiao, M. Chen and H. Gao, *Adv. Sci.*, 2022, **9**, e2103836.
- 5 Z. Ge and S. Liu, *Chem. Soc. Rev.*, 2013, **42**, 7289–7325.
- 6 Y. Dai, C. Xu, X. Sun and X. Chen, *Chem. Soc. Rev.*, 2017, **46**, 3830–3852.
- 7 Y. X. Fang, N. Zhang and Y. J. Liu, *Chemistry of Life*, 2020, vol. 40, pp. 1693–1699.
- 8 F. Bruno, F. Arrigoni, S. Mariani, A. Splendiani, E. Di Cesare, C. Masciocchi and A. Barile, *Radiol. Med.*, 2019, **124**, 243–252.
- 9 C. Wang, Z. Wang, T. Zhao, Y. Li, G. Huang, B. D. Sumer and J. Gao, *Biomaterials*, 2018, **157**, 62–75.
- 10 Q. Fu, R. Zhu, J. Song, H. Yang and X. Chen, *Adv. Mater.*, 2019, **31**, e1805875.
- 11 D. Fischerova, G. Santos, L. Wong, V. Yulzari, R. J. Bennett, P. Dundr, A. Burgetova, P. Barsa, G. Szabo, N. Sousa, U. Scovazzi and D. Cibula, *Ultrasound Obstet. Gynecol.*, 2023, **62**, 727–738.
- 12 E. Seeram, *Radiol. Technol.*, 2018, **89**, 279CT–302CT.
- 13 Y. Zhang and J. Yu, *Diagn. Interv. Radiol.*, 2020, **26**, 176–182.
- 14 Y. D. Xiao, R. Paudel, J. Liu, C. Ma, Z. S. Zhang and S. K. Zhou, *Int. J. Mol. Med.*, 2016, **38**, 1319–1326.
- 15 J. H. Kim, S. J. Byun, S. G. Park, Y. K. Oh and S. K. Baek, *Cancer Res. Treat.*, 2012, **44**, 187–194.
- 16 J. H. Correia, J. A. Rodrigues, S. Pimenta, T. Dong and Z. Yang, *Pharmaceutics*, 2021, **13**, 1332.
- 17 S. Kwiatkowski, B. Knap, D. Przystupski, J. Saczko, E. Kedzierska, K. Knap-Czop, J. Kotlinska, O. Michel, K. Kotowski and J. Kulbacka, *Biomed. Pharmacother.*, 2018, **106**, 1098–1107.
- 18 M. W. Dewhirst, Y. Cao and B. Moeller, *Nat. Rev. Cancer*, 2008, **8**, 425–437.
- 19 L. P. Zhao, R. R. Zheng, H. Q. Chen, L. S. Liu, X. Y. Zhao, H. H. Liu, X. Z. Qiu, X. Y. Yu, H. Cheng and S. Y. Li, *Nano Lett.*, 2020, **20**, 2062–2071.
- 20 S. Wilhelm, A. J. Tavares, Q. Dai, S. Ohta, J. Audet, H. F. Dvorak and W. C. W. Chan, *Nat. Rev. Mater.*, 2016, **1**, 16014.
- 21 K. N. Sugahara, T. Teesalu, P. P. Karmali, V. R. Kotamraju, L. Agemy, D. R. Greenwald and E. Ruoslahti, *Science*, 2010, **328**, 1031–1035.
- 22 X. Cun, J. Chen, S. Ruan, L. Zhang, J. Wan, Q. He and H. Gao, *ACS Appl. Mater. Interfaces*, 2015, **7**, 27458–27466.
- 23 H. Shokrollahi, *Mater. Sci. Eng., C*, 2013, **33**, 4485–4497.
- 24 Y. Zhou, G. Quan, Q. Wu, X. Zhang, B. Niu, B. Wu, Y. Huang, X. Pan and C. Wu, *Acta Pharm. Sin. B*, 2018, **8**, 165–177.
- 25 C. Bharti, U. Nagaich, A. K. Pal and N. Gulati, *Int. J. Pharm. Invest.*, 2015, **5**, 124–133.
- 26 Madhwi, R. Kumar, P. Kumar, B. Singh, G. Sharma, O. P. Katare and K. Raza, *Int. J. Pharm.*, 2017, **519**(1–2), 138–144.

